You are using an outdated browser. Please upgrade your browser to improve your experience.

ravulizumab

Ligand Summary
Description
Ravulizumab-cwvz is a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a (the proinflammatory anaphylatoxin) and C5b (the initiating subunit of the terminal complement complex [C5b-9]) and preventing the generation of the terminal complement complex C5b9. ULTOMIRIS inhibits terminal complement-mediated intravascular hemolysis in patients with PNH.
Synonyms & Links
DrugCentral: 5322
LyCHI:  ravulizumab


loading...
Target Activities